Structure Therapeutics’ aleniglipron Phase 2 shows ~16% placebo-adjusted weight loss; a best-in-class oral GLP-1 with strong cash runway.
Morning Overview on MSN
AI study of protein nanoribbons points to new design rules
Researchers at Pacific Northwest National Laboratory used artificial intelligence to analyze protein nanoribbons, pointing to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results